Zhejiang Beisheng Pharmaceutical Hansheng Pharmaceutical

Zhejiang Beisheng Pharmaceutical Hansheng Pharmaceutical Co., Ltd., founded in 1996 and based in Dongyang, Zhejiang Province, China, is a comprehensive pharmaceutical company engaged in the research, development, manufacturing, and contract development and manufacturing (CDMO) of chemical drugs and biologics. The company holds the distinction of being the first in China to achieve GMP certification for a genetic engineering product. Its commercial portfolio features key products such as recombinant human interferon alpha-2b, doxofylline injection, levocarnitine injection, desloratadine oral solution, and memantine hydrochloride oral solution. These products span multiple therapeutic areas, including respiratory, infectious, neurological, and digestive diseases. Hansheng Pharmaceutical operates several advanced GMP-compliant production lines for small-volume injections, lyophilized powders, and solid oral dosages, serving both domestic and international markets.